Marvin E Bishop, MD in Winchester, KY - Dermatology

Marvin E Bishop, MD is a Dermatology physician based in Winchester, Kentucky. Marvin E Bishop is licensed to practice in Kentucky (license number 16979) and his current practice location is 218 S Maple St, Winchester, Kentucky. He can be reached at his office (for appointments etc.) via phone at (859) 745-2861.

NPI number for Marvin E Bishop is 1518937523 and his current mailing address is 218 S Maple St, Winchester, Kentucky. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1518937523.

Contact Information

	Marvin E Bishop, MD
	218 S Maple St, Winchester, KY 40391
	(859) 745-2861
	(859) 745-1978

Physician's Profile

Full Name	Marvin E Bishop
Gender	Male
Speciality	Dermatology
Location	218 S Maple St, Winchester, Kentucky
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1518937523
Provider Enumeration Date: 01/23/2006
Last Update Date: 09/04/2007

Medical Identifiers

Medical identifiers for Marvin E Bishop such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1518937523	NPI	-	NPPES
64169790	Medicaid	KY

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207N00000X	Dermatology	16979 (Kentucky)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Marvin E Bishop is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Marvin E Bishop, MD 218 S Maple St, Winchester, KY 40391 Ph: (859) 745-2861	Marvin E Bishop, MD 218 S Maple St, Winchester, KY 40391 Ph: (859) 745-2861

News Archive

Human Genome Sciences, 4-Antibody sign collaboration agreement

4-Antibody AG today announced the signing of a collaboration agreement with Human Genome Sciences (HGS) to discover and develop fully human therapeutic antibodies.

Regenstrief Institute to tackle catastrophic disease outbreaks on behalf of CDC

The Centers for Disease Control has awarded the Indiana University School of Medicine a $2.6 million initial contract with the possibility of nearly $10 million in funding over 5 years to accelerate the real-time ability of local, state and regional entities to share data and information to enhance rapid response to and management of potentially catastrophic infectious disease outbreaks and other public health emergencies.

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium.

Developing a precision 'Trojan Horse' nanotherapy to treat breast cancer

With a nearly $2.6 million grant from the National Institutes of Health, Michigan State University researchers are using nanoscopic particles to turn the body's own cells into weapons that cancer won't see coming.

Risk-based treatment approach should be considered for patients with hypertension

Blood pressure-lowering treatment should target patients at greatest cardiovascular risk and not just those with the highest baseline levels, suggest findings of a meta-analysis.

Marvin E Bishop, MD - Dermatology in Winchester, KY